Lyra Therapeutics Accounts Payable

Lyra Therapeutics (LYRA) currently reports a accounts payable of $660K as of December 2025. That compares with $1.2M in the prior-year period — down 43.8% year over year. Use the charts on this page to explore Lyra Therapeutics's accounts payable history and peer comparisons.

Lyra Therapeutics's accounts payable decreased from $1.2M to $660K — a 43.8% year-over-year decrease (period ending December 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Lyra Therapeutics reported $660K in accounts payable as of December 2025. That compares with $1.2M in the prior-year period — down 43.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current accounts payable of $660K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Lyra Therapeutics, and consider following LYRA for alerts when major investors trade the stock.

Lyra Therapeutics is classified in the Healthcare sector. On accounts payable, it currently shows $660K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LYRA with unrelated industries.